J. Goldman & CO LP Acadia Pharmaceuticals Inc Transaction History

J. Goldman & CO LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $167,751 - $237,100	-8,647 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$25.02 - $54.99 $216,347 - $475,498	8,647 New	8,647 $223,000
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $364,818 - $439,909	-15,644 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$16.17 - $27.38 $252,963 - $428,332	15,644 New	15,644 $420,000
Q3 2018 Nov 14, 2018	SELL	$13.03 - $21.81 $1.61 Million - $2.7 Million	-123,769 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $1.87 Million - $2.76 Million	123,769 New	123,769 $1.89 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.73B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.